PrescrAIP : A Pan-European Study on Current Treatment Regimens of Auto-Immune Pancreatitis by Lanzillotta, Marco et al.
STUDY PROTOCOL
published: 05 August 2020
doi: 10.3389/fmed.2020.00408
Frontiers in Medicine | www.frontiersin.org 1 August 2020 | Volume 7 | Article 408
Edited by:
Enrique de-Madaria,
Hospital General Universitario de
Alicante, Spain
Reviewed by:
Suresh Chari,
University of Texas MD Anderson
Cancer Center, United States
Tooru Shimosegawa,
Tohoku University, Japan
*Correspondence:
Marco Lanzillotta
lanzillotta.marco@hsr.it
Kasper A. Overbeek
k.overbeek@erasmusmc.nl
†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Gastroenterology,
a section of the journal
Frontiers in Medicine
Received: 22 March 2020
Accepted: 29 June 2020
Published: 05 August 2020
Citation:
Lanzillotta M, Vinge-Holmquist O,
Overbeek KA, Poulsen JL, Demirci AF,
Macinga P, Löhr M and Rosendahl J
(2020) PrescrAIP: A Pan-European
Study on Current Treatment Regimens
of Auto-Immune Pancreatitis.
Front. Med. 7:408.
doi: 10.3389/fmed.2020.00408
PrescrAIP: A Pan-European Study on
Current Treatment Regimens of
Auto-Immune Pancreatitis
Marco Lanzillotta 1*†, Olof Vinge-Holmquist 2†, Kasper A. Overbeek 3*, Jakob L. Poulsen 4,
A. Fatih Demirci 5, Peter Macinga 6, Matthias Löhr 7 and Jonas Rosendahl 8 on behalf of the
PrescrAIP Study Group
1Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), San Raffaele Scientific Institute, Milan, Italy,
2Department of Gastroenterological Surgery, Akershus University Hospital, Loerenskog, Norway, 3Department of
Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, Netherlands, 4Centre for Pancreatic
Diseases, Department of Gastroenterology & Hepatology, Aalborg University Hospital, Aalborg, Denmark, 5Department of
Internal Medicine, Marmara University Research and Education Hospital, Istanbul, Turkey, 6Department of Gastroenterology
and Hepatology, Institute for Clinical and Experimental Medicine, Prague, Czechia, 7Gastroenterology and Hepatology,
Gastrocentrum, Karolinska University Hospital, Karolinska Universitetssjukhuset, Stockholm, Sweden, 8Department of
Internal Medicine I, Martin Luther University, Halle (Saale), Germany
Introduction: Treatment of autoimmune pancreatitis (AIP) is based solely on consensus
and has yet to become standardized. Consequently, therapeutic regimens vary greatly
between countries and centers, and largely depend on the experience of the physician. At
this moment, the optimal regimen for inducing disease remission and preventing relapse
is unknown.
Objectives: The primary objective of this study is to describe current treatment regimens
used in Europe, and to compare their effectiveness in inducing remission and preventing
and treating relapse. The secondary objectives are: to identify risk factors for relapse; to
assess the diagnostic accuracy of the Unified-AIP criteria; to assess the performance
of the M-ANNHEIM score for predicting relapse; and to assess long-term outcomes
including pancreatic exocrine insufficiency and pancreatic cancer.
Methods: This is an international, retrospective, observational cohort study, performed
in over 40 centers from 16 European countries. Eligible are all patients diagnosed
with AIP from 2005 onwards, regardless of the used diagnostic criteria. Data on study
subjects will be retrieved from the hospital’s electronic medical records and registered
with a standardized, web-based, electronic case report form (eCRF). To compare the
effectiveness of treatment regimens in inducing remission, preventing relapse, and
treating relapse, subjects will be stratified in groups based on: type of therapy; initial
therapy dose; cumulative therapy dose; therapy tapering speed and duration; and having
received maintenance therapy or not.
Ethics and Dissemination: Ethical and/or institutional review board approvals are
obtained by all participating centers according to local regulations. The study complies
with the General Data Protection Regulation (GDPR). All manuscripts resulting from the
study will be submitted to peer-reviewed journals.
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Conclusion: This is the first pan-European retrospective registry for AIP. It will produce
the first large-scale data on treatment of European patients with AIP, providing answers
on the use and effectiveness of treatment regimens. In the future, this collaboration may
provide a network for continuation into a prospective European registry.
Keywords: autoimmune pancreatitis, IgG4 (autoimmune pancreatitis), glucococorticoids, cohort studies, IgG4
INTRODUCTION
Autoimmune pancreatitis (AIP) has recently been recognized
as an immune-mediated disease of the pancreas with distinct
features (1). It is a rare disease with an annual incidence of
∼3.1/100,000, which varies substantially between geographical
regions (2). To date, two types of autoimmune pancreatitis have
been described (1). Type 1 AIP is the pancreatic manifestation
of IgG4-related disease (IgG4-RD). It shares clinical and
histological hallmarks with IgG4-RD, namely increased serum
Immunoglobulin G4 (IgG4) levels, dense storiform fibrosis,
and IgG4-positive plasma cell infiltration of the affected
organ (3). Type 2 AIP is known as idiopathic duct-centric
pancreatitis and is characterized by neutrophil-mediated duct
destruction, in the form of granulocytic epithelial lesions (GEL)
(4). Both types can cause abdominal pain and jaundice and
can ultimately lead to chronic pancreatitis (1). This in turn,
might even increase the risk of developing pancreatic cancer
(5). Yet, the incidence of these complications has not been
clearly established.
In the last two decades, several efforts have been made to
establish diagnostic criteria (1, 6–8), which are all based on the
combination of clinical, serological, and pathological features.
Nevertheless, AIP cases are still missed or even mistaken for
pancreatic ductal adenocarcinoma (9, 10). As such, sequelae of
chronic pancreatitis with endocrine and exocrine insufficiency
can develop or the diagnosis of type 1 and type 2 AIP is made
after unnecessary surgery (11). In addition, a discrete percentage
of AIP cases does not fulfill diagnostic criteria for type 1 or type
2 AIP and thus are referred to as Not-Otherwise-Specified (NOS)
AIP (1).
All AIP subtypes respond dramatically to steroid treatment
(up to 99% in the different cohorts) (11–14), but the optimal dose
to induce remission remains controversial. Reported induction
doses have ranges between 30 and 60mg daily (11–14) Recently,
other therapeutic options, that induce B-cell depletion, have
also been employed in inducing AIP remission, with promising
results (15, 16). In a cohort from France, the reported efficacy
was 94%with two infusions given inmost patients (17). However,
in spite of the dramatic response to initial treatment, the risk of
relapse within 1 year from disease remission ranges between 30
and 50% (12), being higher in type 1 than in type 2 AIP patients
(12). Several risk factors for AIP relapse have been proposed,
but have not been validated prospectively (11, 12, 18, 19). Due
to the high frequency of relapse after induction, some authors
recommend maintenance treatment with low-dose steroids or
immunomodulators, but the patient group that would benefit
from maintenance is currently unknown (20–26).
Thus far, data on the epidemiology and natural history of
AIP are still scant due to its rarity and its relatively recent
appraisal. Most of the data comes fromAsian or North-American
cohorts, while data on large European cohorts are lacking.
As a consequence, treatment options applied in Europe are
largely based on retrospective studies from Asian and North-
American patients.
We established the PrescrAIP (A Pan-European Study on
Current Treatment Regimens of Auto-immune Pancreatitis)
study network to retrospectively describe the current status of
AIP treatment in Europe on a large scale. In addition, our
effort will create the opportunity for a subsequent international
prospective registry that will be able to provide definite answers
in the future. In particular, in this retrospectivemulticentre study,
we aim to define and compare the AIP treatment regimens
used throughout different European centers, highlighting their
differential impact on disease remission and long-term outcomes.
These results will foster our knowledge of this rare disease,
yielding to better patient care.
OBJECTIVES
The primary objective of this study is to describe AIP treatment
regimens across Europe, and to compare the effectiveness
of treatment regimens in inducing remission, preventing and
treating relapse. The secondary objectives include identifying
risk factors for relapse, assessing the diagnostic accuracy of
the U-AIP criteria (6), assessing the performance of the M-
ANNHEIM score for predicting relapse (19), and assessing long-
term outcomes including pancreatic exocrine insufficiency and
pancreatic cancer. Thirdly, we are aiming to assess whether
standard treatment was altered due to pre-existing diabetes
mellitus, determine the prevalence of diabetes mellitus before and
after steroid treatment, assess glycemic control in patients with
diabetes mellitus and to describe the clinical, radiological and
pathological characteristics of a cohort of patients diagnosed with
AIP through pancreatic resection.
METHODS
Study Design
This is an international, retrospective, observational cohort study
including all AIP patients. We used the Pancreas2000 framework
(www.pancreas2000.org) to create a study network starting with
the six centers in the PrescrAIP core group. Additional European
centers with expertise in the treatment of AIP patients have been
recruited, accumulating to a total of 44 collaborating centers.
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Study Population
Every patient with an AIP diagnosis (type 1, type 2 or NOS-AIP)
will be included, regardless of diagnostic criteria used (U-AIP,
HISORt, ICDC). Patients with AIP diagnosed prior to 2005 will
be excluded due to lack of uniformity in diagnostic standards.
Setting
The collaboration involves a large number of European centers,
most of which are academic hospitals (Figure 1). Starting with
the eight centers of the PrescrAIP core group, the study now
encompasses centers in Germany (12), the United Kingdom (5),
the Netherlands (3), Turkey (3), Italy (3), Spain (3), Norway
(2), Poland (2), Russia (2), Hungary (2), Czech Republic (2),
Lithuania (1), Ukraine (1), Denmark (1), Sweden (1), and
France (1).
Data Collection
Patient data will be collected from the hospitals’ medical records.
Variables were selected to answer the research questions and
meet the objectives of the study. Variables will be recorded
in a REDCap-based (https://www.project-redcap.org) electronic
datasheet (electronic case record form, eCRF), hosted by The
North Denmark Region. The principal investigator of each site
will ensure that the data in the eCRF are accurate, complete
and legible. REDCap is a secure, online application designed to
support data acquisition and storage by providing a shapeable
interface for validated data entry.
Assessment Variables
At the time of inclusion, all relevant variables will be recorded
in the eCRF. These will include variables on demography and
epidemiology, disease characteristics (radiological, laboratory
and clinical), the set of diagnostic criteria employed, treatment
(type, dose, duration), and short and long-term clinical
outcomes. The complete variable list and definitions are reported
in Appendix 1. AIP subtypes will be defined following the
analysis of the above-mentioned variables. Given that patients
with elevated serum IgG4 but without other organ involvement
or biopsy sample can potentially be misdiagnosed, a subgroup
with these characteristics will be created. Then a sensitivity
analysis with and without excluding this subgroup will be
performed to evaluate potential differences in the outcomes.
Study Endpoints
Our primary endpoints consist of remission of disease (defined
as the absence of clinical symptoms and the resolution of
pancreatic abnormalities on imaging), relapse of disease, relapse
rates compared between patients with a low or a high dose
regimen, cumulative maintenance therapy dose and relapse-free
survival time. Our secondary study endpoints are gold standard
diagnostic tools of AIP compared to U-AIP, the prevalence of
pancreatic exocrine insufficiency and the cumulative incidence
of pancreatic ductal adenocarcinoma. The diagnosis of diabetes
mellitus [as defined by the American Diabetes Association
(27)] either before or after steroid treatment is our tertiary
study endpoint.
Statistical Analysis
Continuous, non-normally distributed values will be presented as
median and interquartile range (IQR), unless otherwise specified.
Discrete variables will be presented as frequency (percentage).
Normal distribution of continuous variables will be assessed
with the Kolmogorov–Smirnov algorithm. Normally distributed
variables among the different groups will be compared using
the Student’s t-test. Non-normally distributed variables will be
compared using theMann–WhitneyU-test. Categorical variables
will be analyzed by the Fisher’s exact test or chi-square test.
To compare remission rates, relapse rates, relapse-free
survival and long-term outcomes between participants, we will
stratify participants according to the date of diagnosis, meeting
the different diagnostic criteria, the type of treatment, the
glucocorticoids starting dose, the cumulative dose, tapering
speed, and treatment with maintenance treatment.
Moreover, to assess the impact of the treatment effect being
part of the diagnostic criteria, we will perform sensitivity
analyses comparing the study outcomes between those
classified as AIP regardless of the steroid trial, and those
in whom the diagnosis was dependent on the steroid trial.
Sensitivity analyses will also be performed to compare the
study outcomes including or excluding individuals that do not
meet any available diagnostic criteria, and those classified as
NOS-AIP.
Kaplan-Meier curves will be used to assess time-to-relapse.
Time-to-relapse will be compared between subgroups using
the log-rank test. Univariable and multivariable analyses with
a backward selection procedure will be performed to identify
possible predictors for relapse, based on a Cox-proportional
hazards regression model. A significance threshold of P < 0.05
will be used.
Data from national pancreatic cancer registries will be used
to determine age- and sex-specific incidence rates for pancreatic
ductal adenocarcinoma. Standardized incidence ratios (SIRs) will
be then calculated by obtaining the ratio of the observed to
the expected number of cases, and 95% confidence intervals
(95% CIs).
ETHICS AND DISSEMINATIONS
This study was reviewed and approved by the ethics committees
of the centers in the PrescrAIP core group, namely those
at the San Raffaele Scientific Institute (Milan, Italy), the
South East Regional Committee for Medical and Health
Research Ethics (Oslo, Norway), the Erasmus University Medical
Center (Rotterdam, The Netherlands), the Aalborg University
Hospital (Aalborg, Denmark), the Marmara University School
of Medicine (Istanbul, Turkey), the Institute for Clinical and
Experimental Medicine (Prague, Czech Republic), the Karolinska
University Hospital (Stockholm, Sweden), and the Martin Luther
University Halle-Wittenberg (Halle, Germany). In addition,
participating centers had the protocol reviewed and approved
wherever required by local regulations.
Patients’ data will be collected retrospectively from pre-
existing electronic patient records. Study data will then be
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FIGURE 1 | European centers (dots) involved in the PrescrAIP Study.
collected and managed using a REDCap database hosted at
Aalborg University Hospital, North Denmark Region, Denmark.
All data will be coded (pseudonymized). The key to the
coded data will be stored locally in the participating site, in a
password-protected file controlled by the Principal Investigator,
and separately from any research data. For the German centers
data will be anonymized immediately. When data is exported
from the REDCap system for analysis, the data will be made
completely unidentifiable and potential identifier variables will
be removed. Additional processing of already collected data
for the purpose of scientific research is exempt from specific
consent according to Articles 5(1)(b) and 89(1) of the General
Data Protection Regulation (GDPR). The study adheres to the
Declaration of Helsinki. No patient will be exposed to any
inconvenience in relation to the present study because all data
are obtained retrospectively. The findings of the study will
be published in a peer-reviewed journal and disseminated at
national and international conferences.
DISCUSSION
AIP has only been acknowledged as a discrete entity in the
last 20 years (1), even though the first reports date back to
the 1960’s (28). In the last decade, international efforts led
to the creation of several sets of diagnostic criteria (1, 6–8),
definitely raising awareness on AIP and providing guidelines
for its treatment. Despite significant progress in the field, key
questions related to the pathophysiology, diagnosis, treatment,
and treatment-related complications of AIP remain unanswered.
Therefore, AIP still poses a clinical challenge and the diagnosis
is still overlooked. In particular, the role and efficacy of
glucocorticoids in the induction of remission has been widely
accepted and reported, but the optimal starting dose as well
as tapering speed is far from being elucidated. In addition,
several risk factors for relapse have emerged recently, but only
few derive from large cohorts and none have been validated
prospectively (11, 12, 18, 19). Finally, long term outcomes
in terms of pancreatic exocrine and endocrine dysfunction,
as well as incidence rates of malignancies, have rarely been
addressed, ultimately impacting on patients’ nutritional status
and survival (29–31).
To a certain extent, the scarcity of data available can be linked
to the low incidence of AIP. Together with its relatively recent
appraisal, this complicates the implementation of adequately
powered randomized controlled trials. Through an international
European-based, multicenter effort, we plan to shed light on
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this multifaceted condition in order to develop evidence-based
treatment strategies in the future. As such, our aim is to
collect all available AIP cases, reporting clinical, laboratory,
and treatment-related features in order to create an accurate
picture of the current European AIP management and to
obtain novel data on the natural history of AIP in Europe.
Stemming from these, new questions may be formulated and
evaluated in a prospective continuation of the present study.
In addition, as mentioned above, due to the relatively young
age of AIP long-term sequelae have often been overlooked
by seminal studies in this field. Yet, a better knowledge
in the development of pancreatic exocrine and endocrine
(type 3c diabetes or “pancreatogenic” diabetes) insufficiency or
treatment related diabetes is warranted in order to deliver better
quality of life.
This project has several strengths. Based on a multicentre
cohort, this pan-European AIP study will provide a large dataset,
dealt by field experts. Indeed, the vast majority of AIP reports
derive from North-American or Asian cohorts, with most likely
distinct genetic or environmental features that might not be
shared by European AIP patients. Therefore, our study will
plausibly provide a more homogenous AIP population thus far
not included in recent trials. Due to the rarity of AIP, multicentric
collaboration offers the unique possibility of obtaining more
reliable results since larger patients’ cohort can be analyzed.
Moreover, the electronic datasheet will guarantee data quality and
safety and will also stimulate data homogeneity across the various
very heterogeneous countries and practices.
The study does not come without limitations, it being a
descriptive retrospective study. There is a risk of the clinical
and diagnostic guidelines being applied differently throughout
the recruitment period. To mitigate this, we have collected
clinical symptoms, laboratory and radiological findings rather
than using the derivative AIP subtyping of the clinician. For
example, as in most institutions pancreatic biopsies are not
performed, seronegative type 1 AIP confined to the pancreas
could be misdiagnosed as type 2. Conversely, atypical type
2 AIP with elevation of serum IgG4 might be classified as
type 1 AIP. By subgrouping patients according to clinical,
histopathological (where available) and radiological findings we
aim to better judge the AIP subtype of the patient we aim
to better judge the AIP subtype of the patient and increase
transparency and uniformity of the AIP diagnoses made. As
the response to a steroid trial might in some cases establish
the diagnosis of AIP incorrectly, we will perform a subgroup
analysis in patients in whom the AIP diagnosis was based on
the successful steroid trial. Hereby, we will be able to estimate
the effect of this group on the overall results of our analysis.
In addition, we will be enabled to perform sensitivity analyses
in that distinct subgroups, as described above. Lastly, many
patients have a long follow-up, which should strengthen the true
AIP diagnosis.
In conclusion, our work will provide detailed description
on the natural history and management of AIP in Europe,
representing a unique framework for future prospective studies
that may be able to provide definite answers to the questions that
remain after the current retrospective evaluation.
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